Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Weekly Digest
Fed. Cir.

Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 17-2557 (Fed. Cir. Jan. 16, 2019)

Errata Correction sheet to a previously issued opinion
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 17-2557
Decided
January 16, 2019
Judge
Per curiam
Document
Nonprecedential Opinion
Length
2 pages

NOTE: This order is nonprecedential. United States Court of Appeals

for the Federal Circuit

TRIS PHARMA, INC.,

Plaintiff-Appellant

v.

ACTAVIS LABORATORIES FL, INC.,

Defendant-Appellee

2017-2557, 2017-2559, 2017-2560

Appeals from the United States District Court for the District of Delaware in Nos. 1:14-cv-01309-GMS, 1:15-cv-00393-GMS, 1:15-cv-00969-GMS, Judge Gregory M. Sleet.

ON PETITION FOR PANEL REHEARING

Before NEWMAN, O’MALLEY, and CHEN, Circuit Judges.

O R D E R

Actavis Laboratories FL, Inc. petitions for panel rehearing of this court’s November 20, 2018 opinion, asking the panel to “eliminate [a] factual error from its decision to ensure that the district court has a proper understanding of what issues it must address on remand.”2 2 TRIS PHARMA, INC. v. ACTAVIS LABORATORIES FL, INC.

Specifically, Actavis directs us to a passage of our opinion on pages 13 and 14 (including footnote 4) that discusses the district court’s incomplete analysis of the Biederman article and concludes that the district court never cited a particular passage of Biederman in its decision. Actavis points out that the Biederman article is cited on page 44 of the district court’s decision (J.A. 47) and requests that we amend our decision to take this fact into account.

To avoid any confusion as to our instruction to the district court on remand, we grant the petition for the limited purpose of amending our earlier opinion. The sentence beginning at page 13, line 21 is amended to read: “For instance, the district court never made explicit findings that Daytrana®, Concerta®, Metadate CD®, and/or Scicinski also teach a 45-minute onset of action and 12-hour duration of effect.” The sentence beginning in the second line of page 14 of Footnote 4 is amended to read: “However, the district court never cited this passage in its opinion as teaching both a 30-minute onset of action and a 12-hour duration of effect.”

Accordingly,

IT IS ORDERED THAT:

The petition is granted to the limited extent noted above. The court shall withdraw the opinion and judgment issued November 20, 2018, and issue a modified version of the opinion incorporating the amendments described above. A new judgment shall issue as of the date of issuance of the modified opinion.

FOR THE COURT

January 16, 2019 /s/ Peter R. Marksteiner

Date Peter R. Marksteiner Clerk of Court

.

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 17-2557 (Fed. Cir. Jan. 16, 2019).

Record ID
CAFC-17-2557-20190116
Permalink
https://patentcasewatch.com/opinions/CAFC-17-2557-20190116

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.